IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn?
Haemolytic disease of the newborn (HDN) can be prevented by the passive administration of anti-D to the mother. The most accepted theory to describe this activity of anti-D is based upon its ability to clear opsonized erythrocytes before their recognition by the maternal immune system. We examined this hypothesis using a murine model of immunity to foreign erythrocytes. Whereas transfusion of foreign erythrocytes into mice induced immunoglobulin (Ig)M and IgG antibodies specific for the erythrocytes, these humoral immune responses were inhibited when the erythrocytes were opsonized with IgG. To specifically determine if immunological evasion occurs with these opsonized erythrocytes, we examined T-cell responses from these mice. An erythrocyte-specific T-cell response was clearly detected. We then tested whether phagocytosis of opsonized erythrocytes is sufficient to prevent the antibody response. We exposed mononuclear phagocytic cells to sheep red blood cells (SRBC) in vitro and then adoptively transferred the phagocytic cells to recipient mice; opsonized SRBC unexpectedly increased, rather than decreased, the antibody response. These data indicate that removal of opsonized erythrocytes by phagocytic cells does not prevent their immunological recognition and suggest that antigen clearance may not be the predominant mechanism of anti-erythrocyte action in downregulating the humoral immune response.
Brinc
Davor
D
The Canadian Blood Services, Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada.
Le-Tien
Hoang
H
Crow
Andrew R
AR
Freedman
John
J
Lazarus
Alan H
AH
D000818:Animals; D000917:Antibody Formation; D001402:B-Lymphocytes / Q000276:immunology; D004899:Erythroblastosis, Fetal / Q000276:immunology / Q000517:prevention & control*; D004912:Erythrocytes / Q000502:physiology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007165:Immunosuppression Therapy; D007231:Infant, Newborn; D007518:Isoantibodies / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D009895:Opsonin Proteins; D010587:Phagocytosis; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin; D012756:Sheep; D013601:T-Lymphocytes / Q000276:immunology
D007074:Immunoglobulin G; D007518:Isoantibodies; D009895:Opsonin Proteins; C061961:RHO(D) antibody; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin